arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Zai Lab Ltd

ZLAB
$26.45 ▲ +0.05 (+0.19%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
32 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Zai Lab Ltd faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $29.5B
Dividend Yield
Revenue Growth -3.3%
Op. Margin -71.9%
ROIC -12.4%
FCF / Share $-0.06
Trailing P/E
Price / Book 48.9x
FCF Yield
Debt / Equity 0.39
info Valuation on last close. End-of-day price, Sep 23, 2026.

32-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$106.31M
↓ -3.3%
Net Income Profit after all expenses
$-51.02M
↓ -5.3%
Operating Margin Operating profit as % of sales
-71.9%
↓ -3.3% 5th
FCF / Share Free cash flow per share
$-0.06
↓ -389.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
6
Returns
26
Financial Health
41
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 12 years · 32 quarters